DGAP-News: ABIVAX / Key word(s): Study 
Abivax completes induction treatment of last patient in ABX464 phase 2b clinical study in ulcerative colitis 
2021-04-14 / 18:30 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Abivax completes induction treatment of last patient in ABX464 phase 2b clinical study in ulcerative colitis 
  . 16-weeks induction treatment with ABX464 in phase 2b clinical study in ulcerative colitis completed for the 254 
    patients enrolled, with reduction of Total Mayo Score after 8 weeks as primary endpoint 
  . Top-line data of induction phase to become available in the second half of May 2021 
  . 48-weeks maintenance treatment with ABX464 in phase 2b clinical study in ulcerative colitis now fully enrolled, 
    with top-line data to become available in Q1 2022 
  . Start of clinical phase 3 program in ulcerative colitis expected by year end 
  . KOL webcast scheduled on Tuesday, April 20, 2021 at 1:30 pm CEST with Prof. Bruce Sands, M.D., M.S. to discuss 
    ulcerative colitis, existing and future treatment options, and current unmet needs 
PARIS, France, April 14, 2021 - 6:30 p.m. (CEST) - Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage 
biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory 
diseases, viral infections, and cancer, today announces the completion of 16-weeks of induction treatment with 
different doses of ABX464 or placebo in its clinical phase 2b study for the treatment of moderate-to-severe ulcerative 
colitis (UC). Top-line data will become available in the second half of next month. 
The first patient was enrolled into the double-blind, placebo-controlled, dose ranging phase 2b clinical trial with 
ABX464 in UC in August 2019 and recruitment of 254 patients was completed in December 2020. The last patient has now 
completed the 16-weeks induction treatment. 
Ahead of the data read-out, the Company will host a webcasted key opinion leader (KOL) event on Tuesday, April 20, 2021 
at 1:30 pm CEST (7:30 am EDT) with Prof. Bruce Sands, M.D., M.S., Chief of the Division of Gastroenterology at the 
Mount Sinai School of Medicine in New York, NY. Dr. Sands will discuss UC, current and future treatments and unmet 
needs, and Abivax's senior management will provide an update on the Company and the potential of ABX464 to become a 
safe and effective new treatment option. 
Sophie Biguenet, M.D., CMO of Abivax, said: "We are very much looking forward to communicating the results of the 
16-weeks phase 2b induction study during the second half of May this year. These data will provide valuable information 
on the potential of ABX464 to become a well-tolerated, oral, easy-administrable, short- and long-term effective novel 
treatment option for the many patients suffering from moderate-to-severe UC. In parallel, the phase 2b maintenance 
study is continuing as planned and we are preparing for our phase 3 program in UC, expected to start by year end." 
Prof. Hartmut J. Ehrlich, M.D., CEO of Abivax, said: "The clinical phase 2b top-line read-outs in UC next month will 
give us more visibility on the strategic options for the Company. We will carefully evaluate and select the most 
attractive path forward to create shareholder value. Partnering with a large pharma or biotech company remains our 
strategic priority." 
The randomized, double-blind and placebo-controlled phase 2b induction trial had four arms: three once-daily oral 
ABX464 treatment groups (25 mg, 50 mg and 100 mg) and one placebo group. The study is conducted in 130 study centers in 
15 European countries, Canada and the US under the leadership of its principal investigator, Prof. Séverine Vermeire, 
M.D., Ph.D., University Hospitals Leuven, Belgium. Prof. William Sandborn, M.D., University of California San Diego 
Health, serves as the principal investigator for the US. 
All patients who completed the induction study had the option to enroll into the subsequent open-label maintenance 
study for up to two years to confirm the long-term safety and efficacy profile of ABX464. During this maintenance 
period, patients are being treated in an open label fashion with 50mg of once-daily oral ABX464. Abivax is using IQVIA 
as partner, a global premier CRO, to successfully conduct its clinical trials with ABX464 for the treatment of chronic 
inflammatory diseases. 
At present, more than 800 patients have been treated with ABX464 across different indications, including UC. Some of 
these patients are in their fourth year of continuous daily dosing within the ongoing phase 2a maintenance study. 
Abivax reported excellent induction (after 8 weeks) as well as maintenance (after one and two-years) safety and 
efficacy data from the ABX464 UC phase 2a maintenance study with 50 mg once-daily oral ABX464 in patients with 
moderate-to-severe UC. After 12 months of treatment, 75% of the patients were in clinical remission. After the second 
year of continued treatment, 69% of patients were in clinical remission and 94% benefited from a clinical response. 
***** 
Abivax will host a virtual KOL event as webcast on Tuesday, April 20, 2021 at 1:30 pm CEST (7:30 am EDT), ahead of the 
data read-out of its ABX464 phase 2b clinical study in UC. Prof. Bruce Sands, M.D., M.S., Chief of the Division of 
Gastroenterology at the Mount Sinai School of Medicine in New York City, NY, will provide expert information on 
existing and future treatment options for UC, including current unmet medical needs. In addition, Abivax will provide 
an update on the safety and efficacy of ABX464 as it applies to UC. 
To participate in the webcast, please follow the weblink: https://media.rampard.com/20210420/ 
***** 
About Abivax (www.abivax.com) 
Abivax, a clinical stage biotechnology company, is developing novel therapies that modulate the body's natural immune 
machinery to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax is listed on 
Euronext compartment B (ISIN: FR0012333284 - Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug 
candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular 
carcinoma. More information on the company is available at www.abivax.com. Follow us on Twitter @ABIVAX_. 
Contacts 
Abivax                  Investors                      Press Relations & Investors Europe 
Communications          LifeSci Advisors               MC Services AG 
Regina Jehle            Chris Maggos                   Anne Hennecke 
regina.jehle@abivax.com chris@lifesciadvisors.com      anne.hennecke@mc-services.eu 
+33 6 24 50 69 63       +41 79 367 6254                +49 211 529 252 22 
Public Relations France Public Relations France        Public Relations USA 
Actifin                 DGM Conseil                    Rooney Partners LLC 
Ghislaine Gasparetto    Thomas Roborel de Climens      Marion Janic 
ggasparetto@actifin.fr  thomasdeclimens@dgm-conseil.fr mjanic@rooneyco.com 
+33 6 21 10 49 24       +33 6 14 50 15 84              +1 212 223 4017 

DISCLAIMER

This press release contains forward-looking statements, forecasts and estimates (including patient recruitment) with respect to certain of the Company's programs. Although the Company believes that its forward-looking statements, forecasts and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors that have been deemed reasonable, such forward-looking statements, forecasts and estimates are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated in such forward-looking statements, forecasts and estimates. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorité des Marchés Financiers pursuant to its legal obligations including its registration document (Document d'Enregistrement Universel). Furthermore, these forward-looking statements, forecasts and estimates are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law. This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell, or the solicitation of an offer to purchase or subscribe securities of the Company in any jurisdiction, in particular in France. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgement. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions. -----------------------------------------------------------------------------------------------------------------------

2021-04-14 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de -----------------------------------------------------------------------------------------------------------------------

1184882 2021-04-14

(END) Dow Jones Newswires

April 14, 2021 12:30 ET (16:30 GMT)